Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
19 Jan 2021
Historique:
received: 12 08 2020
accepted: 06 01 2021
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 29 1 2021
Statut: epublish

Résumé

Diabetes is a risk factor for infection with coronaviruses. This study describes the demographic, clinical data, and outcomes of critically ill patients with diabetes and Middle East Respiratory Syndrome (MERS). This retrospective cohort study was conducted at 14 hospitals in Saudi Arabia (September 2012-January 2018). We compared the demographic characteristics, underlying medical conditions, presenting symptoms and signs, management and clinical course, and outcomes of critically ill patients with MERS who had diabetes compared to those with no diabetes. Multivariable logistic regression analysis was performed to determine if diabetes was an independent predictor of 90-day mortality. Of the 350 critically ill patients with MERS, 171 (48.9%) had diabetes. Patients with diabetes were more likely to be older, and have comorbid conditions, compared to patients with no diabetes. They were more likely to present with respiratory failure requiring intubation, vasopressors, and corticosteroids. The median time to clearance of MERS-CoV RNA was similar (23 days (Q1, Q3: 17, 36) in patients with diabetes and 21.0 days (Q1, Q3: 10, 33) in patients with no diabetes). Mortality at 90 days was higher in patients with diabetes (78.9% versus 54.7%, p < 0.0001). Multivariable regression analysis showed that diabetes was an independent risk factor for 90-day mortality (odds ratio, 2.09; 95% confidence interval, 1.18-3.72). Half of the critically ill patients with MERS have diabetes; which is associated with more severe disease. Diabetes is an independent predictor of mortality among critically patients with MERS.

Sections du résumé

BACKGROUND BACKGROUND
Diabetes is a risk factor for infection with coronaviruses. This study describes the demographic, clinical data, and outcomes of critically ill patients with diabetes and Middle East Respiratory Syndrome (MERS).
METHODS METHODS
This retrospective cohort study was conducted at 14 hospitals in Saudi Arabia (September 2012-January 2018). We compared the demographic characteristics, underlying medical conditions, presenting symptoms and signs, management and clinical course, and outcomes of critically ill patients with MERS who had diabetes compared to those with no diabetes. Multivariable logistic regression analysis was performed to determine if diabetes was an independent predictor of 90-day mortality.
RESULTS RESULTS
Of the 350 critically ill patients with MERS, 171 (48.9%) had diabetes. Patients with diabetes were more likely to be older, and have comorbid conditions, compared to patients with no diabetes. They were more likely to present with respiratory failure requiring intubation, vasopressors, and corticosteroids. The median time to clearance of MERS-CoV RNA was similar (23 days (Q1, Q3: 17, 36) in patients with diabetes and 21.0 days (Q1, Q3: 10, 33) in patients with no diabetes). Mortality at 90 days was higher in patients with diabetes (78.9% versus 54.7%, p < 0.0001). Multivariable regression analysis showed that diabetes was an independent risk factor for 90-day mortality (odds ratio, 2.09; 95% confidence interval, 1.18-3.72).
CONCLUSIONS CONCLUSIONS
Half of the critically ill patients with MERS have diabetes; which is associated with more severe disease. Diabetes is an independent predictor of mortality among critically patients with MERS.

Identifiants

pubmed: 33468070
doi: 10.1186/s12879-021-05771-y
pii: 10.1186/s12879-021-05771-y
pmc: PMC7814976
doi:

Substances chimiques

Adrenal Cortex Hormones 0

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

84

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Epidemiol Glob Health. 2017 Mar;7(1):29-36
pubmed: 27302882
BMC Public Health. 2018 May 2;18(1):574
pubmed: 29716568
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Clin Infect Dis. 2005 Aug 1;41(3):281-8
pubmed: 16007521
Diabet Med. 2006 Jun;23(6):623-8
pubmed: 16759303
Lancet. 2016 Sep 3;388(10048):994-1001
pubmed: 27402381
PLoS Curr. 2010 Mar 09;2:RRN1150
pubmed: 20228857
N Engl J Med. 2013 Aug 1;369(5):407-16
pubmed: 23782161
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Diabet Med. 1997 Jan;14(1):29-34
pubmed: 9017350
Epidemiol Infect. 2018 Nov 05;147:e35
pubmed: 30394248
Clin Infect Dis. 2016 Mar 15;62(6):755-60
pubmed: 26679623
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
PLoS One. 2014 Nov 19;9(11):e112060
pubmed: 25409519
Clin Infect Dis. 2014 Jul 15;59(2):160-5
pubmed: 24723278
Intensive Care Med. 2010 Sep;36(9):1548-55
pubmed: 20229041
Diabetes Care. 2010 Jul;33(7):1491-3
pubmed: 20587722
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1303-1312
pubmed: 28387897
Infect Chemother. 2016 Jun;48(2):118-26
pubmed: 27433382
Epidemics. 2014 Dec;9:40-51
pubmed: 25480133
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
N Engl J Med. 2020 Oct 22;383(17):1645-1656
pubmed: 33026741
N Engl J Med. 2017 Feb 9;376(6):584-594
pubmed: 28177862
Emerg Infect Dis. 2016 Jan;22(1):49-55
pubmed: 26692185
Crit Care Med. 2017 Oct;45(10):1683-1695
pubmed: 28787295
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
pubmed: 31925415
Int J Infect Dis. 2014 Dec;29:301-6
pubmed: 25303830
Sci Rep. 2017 Sep 12;7(1):11307
pubmed: 28900101
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
N Engl J Med. 2015 Feb 26;372(9):846-54
pubmed: 25714162
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Viral Hepat. 2010 Dec;17(12):859-65
pubmed: 20070501

Auteurs

Jesna Jose (J)

Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Department of Mathematics & Computing, Indian Institute of Technology (ISM), Dhanbad, Jharkhand, 826004, India.

Hasan M Al-Dorzi (HM)

Intensive Care Department, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Awad Al-Omari (A)

Department of Intensive Care, College of Medicine, Alfaisal University, Dr Sulaiman Al-Habib Group Hospitals, Riyadh, Saudi Arabia.

Yasser Mandourah (Y)

Military Medical Services, Ministry of Defense, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Fahad Al-Hameed (F)

Department of Intensive Care, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia.

Musharaf Sadat (M)

Intensive Care Department, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Eman Al Qasim (E)

Intensive Care Department, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Basem Alraddadi (B)

Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia.

Abdulrahman Al Harthy (A)

Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia.

Ghaleb A Al Mekhlafi (GA)

Department of Intensive Care Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Abdullah Almotairi (A)

Department of Critical Care Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.

Kasim Al Khatib (K)

Intensive Care Department, Al-Noor Specialist Hospital, Makkah, Saudi Arabia.

Ahmed Abdulmomen (A)

Department of Critical Care Medicine, King Saud University, Riyadh, Saudi Arabia.

Ismael Qushmaq (I)

Section of Critical Care Medicine, Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.

Anees A Sindi (AA)

Department of Anesthesia and Critical Care, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Ahmed Mady (A)

Intensive Care Department, King Saud Medical City, Riyadh, Saudi Arabia.
Tanta University Hospitals, Tanta, Egypt.

Othman Solaiman (O)

Intensive Care Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Rajaa Al-Raddadi (R)

Department of Community Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Khalid Maghrabi (K)

Intensive Care Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Ahmed Ragab (A)

Intensive Care Department, King Fahd Hospital, Jeddah, Saudi Arabia.

Ayman Kharaba (A)

Department of Critical Care, King Fahad Hospital, Ohoud Hospital, Al-Madinah, Saudi Arabia.

Sarah Shalhoub (S)

Department of Medicine, Division of Infectious Diseases, University of Western Ontario, London, Canada.
King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.

Abdulsalam M Al-Aithan (AM)

Department of Medicine, Critical Care Division, King Abdulaziz Hospital, Al Ahsa, Saudi Arabia.

Gajendra K Vishwakarma (GK)

Department of Mathematics & Computing, Indian Institute of Technology (ISM), Dhanbad, Jharkhand, 826004, India.

Atanu Bhattacharjee (A)

Homi Bhaba National Institute, Section of Biostatistics, Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai, India.

Yaseen M Arabi (YM)

Intensive Care Department, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. arabi@ngha.med.sa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH